1. Report Introduction 2. Secondary Progressive Multiple Sclerosis (SPMS) 2.1. Secondary Progressive Multiple Sclerosis (SPMS) Symptoms 2.2. Secondary Progressive Multiple Sclerosis (SPMS) Causes 2.3. Secondary Progressive Multiple Sclerosis (SPMS) Types 2.4. Secondary Progressive Multiple Sclerosis (SPMS) Risk Factors / Complications 2.5. Secondary Progressive Multiple Sclerosis (SPMS) Pathophysiology 2.6. Secondary Progressive Multiple Sclerosis (SPMS) Diagnosis 2.7. Secondary Progressive Multiple Sclerosis (SPMS) Treatment 3. Comparative Analysis of Marketed and Emerging Products 3.1. Marketed Products 3.1.1. Drug A: Company 3.1.1.1. Product Description 3.1.1.2. Regulatory Milestones 3.1.1.3. Product Development Activities 3.1.1.3.1. General Description Table 3.1.1.4. Global Sales 3.1.1.5. Global API Manufacturers for Drug A 3.1.1.5.1. United States 3.1.1.5.2. Europe 3.1.1.5.3. China 3.1.1.5.4. India 3.1.2. Drug B: Company 3.1.2.1. Product Description 3.1.2.2. Regulatory Milestones 3.1.2.3. Product Development Activities 3.1.2.3.1. General Description Table 3.1.2.4. Global Sales 3.1.2.5. Global API Manufacturers for Drug B 3.1.2.5.1. United States 3.1.2.5.2. Europe 3.1.2.5.3. China 3.1.2.5.4. India Complete details in the report 3.1.3. Emerging Therapies - Late Phase 3.1.3.1. List of Phase III drugs for Secondary Progressive Multiple Sclerosis (SPMS) 4. Appendix 5. Report Methodology 5.1. Secondary Research 5.2. Expert Panel Validation

Table 1 : List of Marketed and Emerging Products Table 2 : Drug A Annual Global Sales from 2012-2023 (in USD million) Table 3 : API Manufacturers for Drug A Region wise Table 4 : API Manufacturers for Drug A for the United States Table 5 : API Manufacturers for Drug A for Europe Table 6 :/ API Manufacturers for Drug A for India Table 7 : API Manufacturers for Drug A for China Table 8 : Drug B Annual Global Sales from 2012-2023 (in USD million) Table 9 : API Manufacturers for Drug B Region wise Table 10 : API Manufacturers for Drug B for the United States Table 11 : API Manufacturers for Drug B for Europe Table 12 : API Manufacturers for Drug B for India Table 13 : API Manufacturers for Drug B for China Table 14 : Drug C Annual Global Sales from 2014-2023 (in USD million) Table 15 : API Manufacturers for Drug C Region wise Table 16 : API Manufacturers for Drug C for the United States Table 17 : API Manufacturers for Drug C for Europe Table 18 : API Manufacturers for Drug C for India Table 19 : API Manufacturers for Drug C for China Table 20 : Drug D, Annual Global Sales from 2013-2023 (in USD million) Table 21 : API Manufacturers for Drug D Region wise Table 22 : API Manufacturers for Drug D for the United States Table 23 : API Manufacturers for Drug D for Europe Table 24 : API Manufacturers for Drug D for India Table 25 : API Manufacturers for Drug D for China Table 26 : Drug E Annual Global Sales from 2014-2023 (in USD million) Table 27 : API Manufacturers for Drug E Region wise Table 28 : API Manufacturers for Drug E for the United States Table 29 : API Manufacturers for Drug E for Europe Table 30 : API Manufacturers for Drug E for India Table 31 : API Manufacturers for Drug E for China Table 32 : List of Phase III drugs for Secondary Progressive Multiple Sclerosis (SPMS)Figure 1 : Comparative Analysis of Marketed and Emerging Products Figure 2 : Drug A, Annual Global Sales from 2012-2023 (in USD million) Figure 3 : API Manufacturers for Drug A Region wise Figure 4 : Drug B, Annual Global Sales from 2012-2023 (in USD million) Figure 5 : API Manufacturers for Drug B Region wise Figure 6 : Drug C, Annual Global Sales from 2014-2023 (in USD million) Figure 7 : API Manufacturers for Drug C Region wise Figure 8 : Drug D, Annual Global Sales from 2011-2023 (in USD million) Figure 9 : API Manufacturers for Drug D Region wise Figure 10 : Drug E, Annual Global Sales from 2014-2023 (in USD million) Figure 11 : API Manufacturers for Drug E Region wise